The IDEXX Laboratories IDXX has been underperforming with Q2 earning misses and a reduced outlook for 2024. Despite beating its EPS and revenue for Q2 2024, price targets have been cut to $520.00. Q2 headwinds are stemmed from low U.S. clinical visits. However, it has attracted the attention of investors like Sequoia Financial Advisors LLC and Wealth Enhancement Advisory Services LLC, leading to share purchases. Its strong financials and decent stock performance have also caught the market's eye, while other investors like Great Valley Advisor Group Inc. and Czech National Bank have also made significant stock holdings. IDEXX Laboratories IDXX has failed to match the earnings growth rate with a 5-year shareholder return. Despite the misses and reduced outlook, analysts remain optimistic, pointing to EPS growth and the company's rock-solid balance sheet. However, insider stock disposals could signal possible bearish trends. Even with Q2 earning misses and a lowered outlook for 2024, they believe shares will multiply in value.
Idexx Laboratories IDXX News Analytics from Thu, 07 Dec 2023 08:00:00 GMT to Sun, 18 Aug 2024 13:16:11 GMT - Rating -2 - Innovation 5 - Information 6 - Rumor -3
